An Open-Label, Long-Term Extension Study to Evaluate the Safety and Tolerability Deflazacort

NCT02295748 | Completed Phase 1

• 1 other identifier: MP-104-CL-022OLE
• Study Type: interventional
• Target: 24
• Locations: 1 country
• Sites: 4

Brief Summary

This is an open label, long-term extension study in approximately 24 male DMD subjects consisting of children (ages 4-12, inclusive) and adolescents (ages 13-16, inclusive) who participated in the MP-104-CL-005 PK study.

Conditions

Duchenne Muscular Dystrophy

Outcome Measures

Primary Outcomes (1)

• Number, frequency, and severity of adverse events

  Long-term safety and tolerability will be characterized by the number, frequency, and severity of adverse events from Day 1 through End of Study or Early Termination.

  3 years

Study Arms (1)

Deflazacort

EXPERIMENTAL

0.9 mg/kg oral deflazacort (between 2 to 12 x 6mg tablets based on body weight) will be administered daily.

Drug: Deflazacort

Interventions

Deflazacort DRUG

Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects, is used in treating a variety of diseases. Pharmacologically it is an inactive pro-drug which is metabolized rapidly to the active drug 21-desacetyldeflazacort.

Also known as: DFZ

Deflazacort

Eligibility Criteria

• Age: 4 Years+
• Sex: male
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Subject is capable of understanding and complying with protocol requirements.
• Subject or, when applicable, the subject's legally acceptable representative signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.
• If above the age of 7, the subject signs and dates a written, informed assent form (IAF) and any required privacy authorization prior to the initiation of any study procedures. Subjects under age 7 at the time of study entry who turn age 7 will sign and date a written informed assent form (IAF) at the visit following their 7th birthday, if required by the site's IRB.
• Subject participated in and received at least one dose of study medication in the MP-104-CL-005 protocol.
• The subject must have confirmed diagnosis of Duchenne Muscular Dystrophy defined as:
• onset of weakness before 5 years of age;
• proximal muscle weakness;
• increased serum creatine kinase more than 10 times the upper limit of normal (ULN);
• muscle biopsy and dystrophin analyses consistent with DMD or DNA mutation and analysis by PCR or Southern blot techniques to detect gene deletions.
• The subject weighs at least 13 kg and has a body mass index (BMI) of ≤ 40 kg/m2.
• Willingness and ability to comply with scheduled visits, oral drug administration, and study procedures including blood sample draws for safety labs.
• Up to date on all childhood vaccinations, including varicella vaccine (chicken pox).
• Baseline health is judged to be stable based on medical history, physical examination, laboratory profiles, vital signs, or ECGs at screening, as deemed by the Investigator.
• Continuous non smoker who has not used nicotine containing products for at least 3 months prior to the first dose.
• The subject is able to take tablets.

You may not qualify if:

• The subject has received any investigational compound and/or has participated in another clinical study within 90 days prior to study treatment with the exception of MP-104-CL-005, observational cohort studies or non-interventional studies.
• The subject is an immediate family member, study site employee, or is in a dependent relationship with a study site employee who is involved in the conduct of this study (e.g. spouse, parent, child, sibling) or may consent under duress.
• The subject has, in the judgment of the, clinically significant abnormal clinical chemistry laboratory parameters that may affect safety at Day 0.
• The subject has, in the judgment of the Investigator, a history or current medical condition that could affect safety including, but not limited to:
• Major renal or hepatic impairment
• Immunosuppression or other contraindications for corticosteroid treatment
• History of chronic systemic fungal or viral infections
• Diabetes mellitus
• Idiopathic hypocalciuria
• Symptomatic cardiomyopathy at Day 0
• The subject has a history of hypersensitivity or allergic reaction to steroids or their formulations including, but not limited to lactose, sucrose, etc.
• Inability to take tablets as assessed by site investigator.
• Subject is mentally or legally incapacitated or has significant emotional problems at the time of screening visit or expected during the conduct of the study.
• History of any illness that, in the opinion of the PI, might confound the results of the study or poses an additional risk to the subject by their participation in the study.
• Positive urine drug or alcohol results at Day 0.

Sponsors & Collaborators

• PTC Therapeutics: lead

Study Sites (4)

UCLA

Los Angeles, California, 90095, United States

Location

Lurie Children's Hospital

Chicago, Illinois, 60611, United States

Location

University of Rochester

Rochester, New York, 14642, United States

Location

University of Utah

Salt Lake City, Utah, 84112, United States

Location

MeSH Terms

Conditions

Muscular Dystrophy, Duchenne

Interventions

deflazacort

Condition Hierarchy (Ancestors)

Muscular Dystrophies; Muscular Disorders, Atrophic; Muscular Diseases; Musculoskeletal Diseases; Neuromuscular Diseases; Nervous System Diseases; Genetic Diseases, X-Linked; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Study Officials

• Marathon Bioscience Center

  Marathon Pharmaceuticals

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 18, 2014
• First Posted: November 20, 2014
• Study Start: December 1, 2014
• Primary Completion: August 24, 2017
• Study Completion: August 24, 2017
• Last Updated: December 8, 2017

Record last verified: 2017-01

Locations

US (4)